ASH 2022 | OPTIC 3-year update: dose-optimization of 3 starting doses of ponatinib in CP-CML
Jorge Cortes, MD, Augusta University, Augusta, GA, shares insights into the findings of the OPTIC trial (NCT02467270), which compared the efficacy of three different daily starting doses of ponatinib: 45 mg, 30 mg, and 15 mg in patients with chronic phase chronic myeloid leukemia (CP-CML). The study’s findings favor the use of 45 mg as a starting dose for most patients, as it shows the highest efficacy with minimal toxicity. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultant for Pfizer, Novartis, Takeda, Sun Pharma, Rigel and Forma Therapeutics. Dr Cortes’ institution receives research support from Pfizer, Takeda, Novartis and Sun Pharma.
